Modifications in accessibility of membrane glycoproteins, binding of specific ligands and coagulation factor V during the activation of platelets in blood emerging from bleeding time wounds.
Dual color flow cytometric techniques were applied to micro-aliquots of whole blood obtained from bleeding time (BT) wounds. Modifications in platelet activation markers (P-selectin [CD62P]) and lysosomal related protein (UMPS [CD63]), presence of membrane glycoproteins (GPIb [CD42b], GPIIb-IIIa [CD41a], GDIV [CD36], binding of von Willebrand factor (vWF), fibrinogen (Fg) and factor V [FV]) were analyzed in normal donors (n = 10) and in a severe von Willebrand patient (type 3) von Willebrand disease [vWD]). Samples of blood (20 microl) were sequentially removed from BT wound edges for up to 5 min and fixed with paraformaldehyde. Antigens were detected using the corresponding tagged monoclonal antibodies (moAbs) and quantitative results were referred to those found on platelet samples obtained from venous blood obtained from the same individuals. A progressive increase in % of platelets positive for activation dependent antigens (CD62 from 7 +/- 2 to 48 +/- 19% and CD63 from 9 +/- 1 to 44 +/- 8%; initial vs. 4 min) was observed. Accessibility of GPIIb-IIIa epitopes on platelets from BT wounds remained slightly above levels observed in venous blood platelets, despite a progressive increase in the presence of platelets positive for Fgn. Binding of MoAb to GPIV increased at late stages of BT. A moderate decrease in the binding of a moAb to GPIb was observed on platelets obtained at late stages of the BT (14 +/- 9% and 20 +/- 6% at 4 and 5 min, respectively). This apparent decrease in GPIb epitopes paralleled an increased presence of platelets positive for vWF (26 +/- 12 and 38 +/- 15%). Binding of moAb to GPIb always remained above basal levels in platelets obtained from BTs performed in the patient with type 3 vWD. FV levels on platelets coming from the BT persisted at background levels in all the individuals and at all times studied.
Escolar
G
G
Servicio de Hemoterapia y Hemostasia, Hospital Clinic, University of Barcelona, Spain.
Lozano
M
M
Díaz-Ricart
M
M
Rao
G H
GH
Ordinas
A
A
White
J G
JG
D000911:Antibodies, Monoclonal / Q000378:metabolism; D001760:Bleeding Time; D018955:CD36 Antigens / Q000276:immunology / Q000378:metabolism; D005165:Factor V / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D015539:Platelet Activation / Q000502:physiology*; D010976:Platelet Count; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D014842:von Willebrand Diseases / Q000097:blood*; D014841:von Willebrand Factor / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018955:CD36 Antigens; D010980:Platelet Membrane Glycoproteins; D014841:von Willebrand Factor; D005165:Factor V; D005340:Fibrinogen